Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6897038 | 0.92 | PLA2G2A (0.46) | DRD2TBXA2RABCB1P2RX7SLC6A4 | |
| SCHEMBL6889569 | 0.92 | MAPK8 (0.43) | CYP19A1SLC6A3MAPTPLA2G2APOLB | |
| SCHEMBL6690879 | 0.91 | DRD2 (0.47) | DRD2TBXA2RP2RX7SLC6A4SLC6A3 | |
| SCHEMBL6890338 | 0.90 | MAPT (0.44) | DRD2TBXA2RP2RX7SLC6A4SLC6A3 | |
| SCHEMBL6894303 | 0.90 | DRD2 (0.44) | DRD2TBXA2RP2RX7SLC6A4SLC6A3 | |
| SCHEMBL6894657 | 0.89 | MAPT (0.42) | DRD2TBXA2RABCB1P2RX7SLC6A4 | |
| SCHEMBL6892182 | 0.88 | DRD2 (0.43) | DRD2TBXA2RP2RX7SLC6A4SLC6A3 | |
| SCHEMBL6776710 | 0.88 | PLA2G2A (0.41) | CYP19A1ABCB1PLA2G2ACNR1MAPK8 | |
| SCHEMBL6895281 | 0.86 | FAAH (0.44) | DRD2TBXA2RSLC6A4SLC6A3MAPT | |
| SCHEMBL6895025 | 0.86 | GRIN1 (0.45) | DRD2TBXA2RP2RX7POLBCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |